Trial Profile
Improving sunitinib efficacy and tolerability in patients with metastatic clear cell carcinoma of the kidney by using a 14/7 day schedule and toxicity-adjusted dosing
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms ISE TAD 14-7
- 30 Nov 2016 New trial record